- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial
- Study type descriptors: Interventional
- Study aim: To assess whether a 5-day course of nirmatrelvir/ritonavir treatment for patients with acute COVID-19 can reduce the prevalence of persistent symptoms at 3 months compared to placebo
- Number of participants enrolled: Enrollment ongoing
- Study enrolling from to
- Study includes follow-up for 1 year
Study Data
- Adults
- General population
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
External Links
Other information
Funders:
- Haukeland University Hospital
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to